The determination of a suitable  minimum CD34+ cell dose for MM patients aged 65 years and older is critical given that the median age of diagnosis for MM is generally between 65 and 70 years of age and many of these patients may be transplant-eligible [8]. Here, CD34 is linked to Miyoshi myopathy.